Imaging biomarkers in Alzheimer's disease: Added value in the clinical setting

Silvia Morbelli, Matteo Bauckneht, Philip Scheltens

Research output: Contribution to journalReview articleAcademicpeer-review

Abstract

Over the last 20 years the availability of magnetic resonance imaging and positron-emission tomography technologies as well as of cerebrospinal fluid biomarkers has allowed research and clinical approach to Alzheimer's disease (AD) to move towards the earliest manifestations of the disease. This new approach resulted in an increasing knowledge about in-vivo biological and neuropathological processes of each phase of the AD-related damage from preclinical, to mild cognitive impairment, and finally to dementia due to AD. The present narrative review deals with the available data as well as with the unsolved issued related to the incorporation of AD biomarkers into the clinical practice. Ongoing research efforts aiming to better define and implement the use of imaging AD biomarkers in clinical practice according to a patient-centered approach and sustainability for clinical-care systems are also discussed.

Original languageEnglish
Pages (from-to)360-371
Number of pages12
JournalQuarterly Journal of Nuclear Medicine and Molecular Imaging
Volume61
Issue number4
DOIs
Publication statusPublished - 1 Dec 2017

Cite this

@article{b81fb335593148f0a5b665a8d9afdd03,
title = "Imaging biomarkers in Alzheimer's disease: Added value in the clinical setting",
abstract = "Over the last 20 years the availability of magnetic resonance imaging and positron-emission tomography technologies as well as of cerebrospinal fluid biomarkers has allowed research and clinical approach to Alzheimer's disease (AD) to move towards the earliest manifestations of the disease. This new approach resulted in an increasing knowledge about in-vivo biological and neuropathological processes of each phase of the AD-related damage from preclinical, to mild cognitive impairment, and finally to dementia due to AD. The present narrative review deals with the available data as well as with the unsolved issued related to the incorporation of AD biomarkers into the clinical practice. Ongoing research efforts aiming to better define and implement the use of imaging AD biomarkers in clinical practice according to a patient-centered approach and sustainability for clinical-care systems are also discussed.",
keywords = "Alzheimer disease, Amyloidosis, Nerve degeneration, Positron-emission tomography",
author = "Silvia Morbelli and Matteo Bauckneht and Philip Scheltens",
year = "2017",
month = "12",
day = "1",
doi = "10.23736/S1824-4785.17.03011-4",
language = "English",
volume = "61",
pages = "360--371",
journal = "The Quarterly Journal of Nuclear Medicine and Molecular Imaging",
issn = "1824-4785",
publisher = "Edizioni Minerva Medica S.p.A.",
number = "4",

}

Imaging biomarkers in Alzheimer's disease : Added value in the clinical setting. / Morbelli, Silvia; Bauckneht, Matteo; Scheltens, Philip.

In: Quarterly Journal of Nuclear Medicine and Molecular Imaging, Vol. 61, No. 4, 01.12.2017, p. 360-371.

Research output: Contribution to journalReview articleAcademicpeer-review

TY - JOUR

T1 - Imaging biomarkers in Alzheimer's disease

T2 - Added value in the clinical setting

AU - Morbelli, Silvia

AU - Bauckneht, Matteo

AU - Scheltens, Philip

PY - 2017/12/1

Y1 - 2017/12/1

N2 - Over the last 20 years the availability of magnetic resonance imaging and positron-emission tomography technologies as well as of cerebrospinal fluid biomarkers has allowed research and clinical approach to Alzheimer's disease (AD) to move towards the earliest manifestations of the disease. This new approach resulted in an increasing knowledge about in-vivo biological and neuropathological processes of each phase of the AD-related damage from preclinical, to mild cognitive impairment, and finally to dementia due to AD. The present narrative review deals with the available data as well as with the unsolved issued related to the incorporation of AD biomarkers into the clinical practice. Ongoing research efforts aiming to better define and implement the use of imaging AD biomarkers in clinical practice according to a patient-centered approach and sustainability for clinical-care systems are also discussed.

AB - Over the last 20 years the availability of magnetic resonance imaging and positron-emission tomography technologies as well as of cerebrospinal fluid biomarkers has allowed research and clinical approach to Alzheimer's disease (AD) to move towards the earliest manifestations of the disease. This new approach resulted in an increasing knowledge about in-vivo biological and neuropathological processes of each phase of the AD-related damage from preclinical, to mild cognitive impairment, and finally to dementia due to AD. The present narrative review deals with the available data as well as with the unsolved issued related to the incorporation of AD biomarkers into the clinical practice. Ongoing research efforts aiming to better define and implement the use of imaging AD biomarkers in clinical practice according to a patient-centered approach and sustainability for clinical-care systems are also discussed.

KW - Alzheimer disease

KW - Amyloidosis

KW - Nerve degeneration

KW - Positron-emission tomography

UR - http://www.scopus.com/inward/record.url?scp=85031916721&partnerID=8YFLogxK

U2 - 10.23736/S1824-4785.17.03011-4

DO - 10.23736/S1824-4785.17.03011-4

M3 - Review article

VL - 61

SP - 360

EP - 371

JO - The Quarterly Journal of Nuclear Medicine and Molecular Imaging

JF - The Quarterly Journal of Nuclear Medicine and Molecular Imaging

SN - 1824-4785

IS - 4

ER -